Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy

Fuller, Christopher K.; Charlson, John A.; Dankle, Steven K.; Russell, Thomas J.

doi:10.1016/j.jaad.2009.09.035

Cited by 38 publications

(24 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[27] In patients with distant metastases, there are data demonstrating the benefit of vascular endothelial growth factor receptors inhibitor bevacizumab in combination with paclitaxel ChT in improving the quality of life and survival. [28] For metastatic angiosarcoma, ChT is the primary treatment option. [29] However, there is no standard ChT regime.…”

Section: Discussionmentioning

confidence: 99%

Total Scalp Irradiation: The Comparison of Five Different Plans Using Volumetric Modulated Arc Therapy- Simultaneous Integrated Boost (VMAT-SIB) Technique

Rakıcı¹

2017

TJ Oncol

View full text Add to dashboard Cite

OBJECTIVEThe aim of this study was to show that the optimum dosage can be delivered to the target organs at risk (OAR) by radiotherapy, which becomes more complicated because of technical difficulties arising from irregular, convex, and complex geometrical structure of the target, such as scalp irradiation, and because of situations resulting from the necessity of bolus of the lesion and immobilization as well as the proximity to neighboring critical organs using the VMAT-SIB technique. METHODSFive different VMAT-SIB schemes were designed using the Varian Trilogy IX linear accelerator (Varian Medical Systems) for total scalp irradiation and bilateral neck irradiation. These different VMAT scehemes were compared with respect to a dose volume histogram of obtained data, homogeneity, indices, conformity index, OAR, and doses of target volumes. RESULTSThe patient-designed bolus plan 1 with two isocenters was chosen as the most appropriate plan. Plans 2, 3, 4, and 5 were inappropriate plans because the application of the virtual bolus in plan 2 was difficult, plan 3 with one isocenter was unacceptable with respect to the value of conformity index, plan 4 with three isocenters had a matching field, and plan 5 in which different priority values were used had an increase in OAR doses. CONCLUSIONVMAT-SIB can be preferred as an appropriate radiotherapy technique as it can provide optimum and allowable OAR doses in tumors requiring an intensive treatment planning effort.

show abstract

Section: Discussionmentioning

confidence: 99%

Total Scalp Irradiation: The Comparison of Five Different Plans Using Volumetric Modulated Arc Therapy- Simultaneous Integrated Boost (VMAT-SIB) Technique

Rakıcı¹

2017

TJ Oncol

View full text Add to dashboard Cite

show abstract

“…This was supported by the clinical case reported by Raina et al [20] who achieved complete response after treatment with thalidomide alone in the treatment of secondary angiosarcoma. Regarding other anti-angiogenic therapies, there is a small amount of evidence based on case report findings of the benefit of bevacizumab with or without chemotherapy; however none of these cases were breast angiosarcomas [21,22]. …”

Section: Discussionmentioning

confidence: 99%

Thalidomide Combined with Neoadjuvant Chemotherapy in Angiosarcoma of the Breast with Complete Pathologic Response: Case Report and Review of Literature

Alvarado‐Miranda

Bacon-Fonseca

et al. 2013

Breast Care

View full text Add to dashboard Cite

Background: Primary angiosarcoma of the breast is a rare malignancy. Case Report: We report on a 41-year-old female patient who initially presented with locally advanced disease. Core biopsy showed angiosarcoma of the breast, grade 1, CD31-positive. The patient was treated with neoadjuvant systemic chemotherapy based on cisplatin, doxorubicin, and paclitaxel, given concurrently with thalidomide. After treatment completion, the patient underwent radical mastectomy. Pathologic complete response in the breast and axillary lymph nodes was achieved. The patient has no evidence of disease recurrence 6 months after her initial diagnosis. Conclusion: Anti-angiogenic therapy may be considered as part of the management of primary angiosarcoma of the breast

show abstract

“…An open-label phase 2 study of single-agent bevacizumab in angiosarcoma [47] demonstrated an overall response rate of 12% with disease stabilization in 62% of patients (n=26). There additionally have been a number of case reports of activity alone or combined with radiation or paclitaxel [48,49]. Based on these reports and the inherent vascularity of these lesions, bevacizumab is in clinical trials with radiotherapy for STS and in combination with cytotoxics for advanced STS.…”

Section: Angiogenesismentioning

confidence: 99%

Emerging Therapeutic Targets for Soft Tissue Sarcoma

Smith

Riedel

2011

Curr Oncol Rep

View full text Add to dashboard Cite

Soft tissue sarcomas (STS) are malignancies of mesenchymal origin that represent approximately 1% of cancers in adults. Systematic research into the treatment of STS is challenging given its rarity and disease heterogeneity. Despite the ability to histologically subtype STS, only recently has our approach to therapy begun to differentiate along these lines. The purpose of this review is to highlight emerging therapeutic targets and therapies that hold the potential to add to the current state of systemic treatment for STS.

show abstract

Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy

Cited by 38 publications

References 5 publications

Total Scalp Irradiation: The Comparison of Five Different Plans Using Volumetric Modulated Arc Therapy- Simultaneous Integrated Boost (VMAT-SIB) Technique

Total Scalp Irradiation: The Comparison of Five Different Plans Using Volumetric Modulated Arc Therapy- Simultaneous Integrated Boost (VMAT-SIB) Technique

Thalidomide Combined with Neoadjuvant Chemotherapy in Angiosarcoma of the Breast with Complete Pathologic Response: Case Report and Review of Literature

Emerging Therapeutic Targets for Soft Tissue Sarcoma

Contact Info

Product

Resources

About